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Abstract
Background: Preeclampsia (PE) is a common maternal disease that complicates 5 to 10% of
pregnancies and remains as the major cause of maternal and neonatal mortality. Cost-effective
interventions aimed at preventing the development of preeclampsia are urgently needed. However,
the pathogenesis of PE is not well known. Multiple mechanisms such as oxidative stress, endothelial
dysfunction and insulin resistance may contribute to its development. Regular aerobic exercise
recovers endothelial function; improves insulin resistance and decreases oxidative stress.
Therefore the purpose of this clinical trial is to determine the effect of regular aerobic exercise on
endothelial function, on insulin resistance and on pregnancy outcome.
Methods and design: 64 pregnant women will be included in a blind, randomized clinical trial,
and parallel assignment. The exercise group will do regular aerobic physical exercise: walking (10
minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10
minutes) in three sessions per week. Control group will do the activities of daily living (bathing,
dressing, eating, and walking) without counselling from a physical therapist.
Trial registration: NCT00741312.
Background
Preeclampsia is a disease of worldwide distribution,
which complicates 5% to 10% of pregnancies and
remains as the major cause of maternal and neonatal mor-
tality and morbidity [1,2]. The problem is especially
important in developing countries, where maternal mor-
tality ratio is up to twenty fold higher than in developed
countries [1]. In Colombia the high incidence of preec-
lampsia (5.1%), low birth weight (LBW; 13.2%), intrau-
terine growth restriction (IUGR; 7.9%) and perinatal
mortality (3.68 per 1000 live births) is considered a seri-
ous public health problem that needs to be solved [3-5].
Multiple conditions such as maternal age, nulliparity, pre-
vious personal and family history of PE, poor nutrition,
sedentary life styles, residence at high altitudes, and lack
of adequate prenatal care have been associated with an
increased risk for PE. Multiple mechanisms as oxidative
stress, endothelial dysfunction, and insulin resistance,
have been proposed to explain the pathogenesis of the
disease [6-8]. Changes in the production and in the action
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of nitric oxide (NO) have been proposed as the key cause
of endothelial dysfunction in preeclampsia [9]. Moreover,
an increased oxidative stress has been proposed as the
main responsible factor for the changes in the vascular
reactivity observed during PE [9]. I It was originally pro-
posed that the increased concentration and reactivity to
vasoconstrictors observed in PE might be due to a reduc-
tion of vasodilator prostaglandins, that results in an
imbalance between prostacyclin (PGI2) and thromboxane
A2 (TXA2) [10,11]. However, this imbalance in prostaglan-
dins has not been found in early pregnancy in women
who subsequently developed PE [10].
Epidemiological evidence suggests that women who par-
ticipate in programs of regular physical activity have a
reduced risk of developing PE [12,13]. Several studies [14-
19] have found beneficial effects of maternal physical
activity during pregnancy on the delivery, the foetal
growth and preterm delivery. Recently, Dempsey et al.
[20] reported that physically active pregnant women expe-
rienced a 40-70% reduced risk of gestational diabetes as
compared with sedentary women. Other investigations
have reported that recreational physical activity during
pregnancy is associated with a reduced risk of PE [21,22].
Endothelial-dependent vasodilator function can be exam-
ined non-invasively in humans by measuring brachial
artery mediated dilatation [23,24] and it has been demon-
strated that exercise improves flow mediated dilatation
(FMD). In normal pregnancy, flow mediated dilatation
increases throughout pregnancy[25,26] but the effect of
exercise on FMD has not been evaluated in pregnant
women.
Rationale of the study
Evidence supports an inverse association between physi-
cal fitness and several risk factors for PE, including glucose
intolerance, hypercholesterolemia, high blood pressure,
obesity, and markers of systemic inflammation like C-
Reactive Protein (CRP). Furthermore, physical fitness may
protect against PE by intervening at three key stages of its
pathogenesis: 1) Protection against abnormal placental
development, 222 2) Reduction of oxidative stress, and 3)
Reversal of endothelial dysfunction (Figure 1). To date,
only few studies have evaluated the effects of habitual
physical activity on endothelial function, and results have
been controversial. In addition, no studies assessing the
influence of regular aerobic exercise on endothelium-
dependent brachial artery flow-mediated dilatation in
pregnant women have been published. The present study
will be conducted in hope of filling this gap.
Methods/Design
Setting
The trial will be conducted at the Universidad del Valle
(UV). The Ethics Committee of Fundación Cardiovascular
de Colombia (FCV) (Resolution-022/29-UV) approved
the trial. All participants will provide written informed
consent before entering the study.
Design and Population
This is a single blind, randomized controlled clinical trial
to evaluate the effects of a supervised aerobic exercise pro-
gram on endothelium-dependent brachial artery flow-
mediated dilatation in 64 nulliparous pregnant women.
Interested women eligible for the present study will be
invited to a pre-test including an interview (Visit A), and
assessments at the Hospital Cañaveralejo and Laboratory
of Biochemistry of the Universidad del Valle, Cali-Colom-
bia. The first visit will take place between weeks 12 and 20
(Visit B), the second at week 32 (Visit C) and the last one,
after delivery (Visit D).
General objective
To determine the effect of regular aerobic exercise on
endothelium-dependent brachial artery flow-mediated
dilatation, insulin resistance and pregnancy outcome.
Specific objectives
1. To determine the influence of aerobic exercise on the
functional capacity (VO2Max), anthropometry (Fatness,
body mass index [BMI]) and biochemical markers (glu-
cose and lipid profile) in the target population.
2. To study the influence of controlled exercise on
endothelial function of pregnant women.
3. To evaluate the effect of aerobic exercise on biochemical
markers of insulin resistance (HOMA Index).
4. To evaluate the effect of physical exercise on maternal
variables (route of delivery, duration of childbirth, post-
partum complications) and the newborn (APGAR score
and anthropometry).
Outcome measurements and instruments
The primary outcome is the difference on endothelium-
dependent brachial artery flow-mediated dilatation after
three months of regular aerobic exercise. [Time Frame:
Baseline and 32 weeks gestation]
The secondary outcome measures are High Sensitivity C-
Reactive Protein, Nitrates, Nitrites, cyclic cyclic guanosine
monophosphate (cGMP), blood lipid profile and glucose,
HOMA index, anthropometric indicators, functional
capacity (VO2Max), [Time Frame: Baseline and 32 weeks
gestation] and maternal pregnancy outcomes (type deliv-
ery, duration of childbirth, blood pressure evolution,
postpartum complications) and newborn outcomes
(APGAR score and anthropometry), [Time Frame: Deliv-
ery].Trials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
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Expected benefits of exercise during pregnancy Figure 1
Expected benefits of exercise during pregnancy. Solid-line boxes represent the effects of preeclampsia and endothelial 
dysfunction. Dashed-line boxes represent the effects of exercise.Trials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
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Interventions
Exercise Group
Regular aerobic physical exercise: Walking (10 minutes),
aerobic exercise (30 minutes), stretching (10 minutes)
and relaxation exercise (10 minutes) for 3 months. Exer-
cise will be performed during 3 sessions per week. All ses-
sions will be supervised by a physical therapist and a
physical educator. The exercise-program follows the
American College of obstetricians and gynecologist
(ACOG) [27] and the American college of Sports Medi-
cine (ACSM] exercise prescription [28]. Aerobic activities
will be performed at moderate intensity (60-70% of max-
imal heart rate) measured by the 6-20 Borg's rating scale
(PER). Each session will start with a 5 minutes warm up,
followed by 30 minutes of aerobic activity, including a 5
minutes cool down. This is followed by 15 minutes of
exercises circuit strength training of the upper limbs,
lower limbs, and deep abdominal muscles stabilization.
The last 5 minutesconsist of stretching and relaxation
exercises.
Control Group
Activities of daily living: basic activities of daily living
(bathing, dressing, eating, walking) without counselling
from a physical therapist but including 6 sessions of pre-
natal behaviour control during a month [28]. Appendix 1.
Sample size
FMD is a measure of endothelial function validated in sev-
eral population studies, taken as the critical variable to
calculate the sample size. A sample size of 64 subjects was
estimated. The sample size was calculated assuming a spe-
cific difference between the groups of 4% in the FMD after
3 months of treatment; with a maximum standard devia-
tion of 4.5. It was accepted a type I error of 0.05, a power
of 80%, and it was adjusted by 20% [29].
Eligibility
64 pregnant nulliparous women, healthy, 16 to 30 years
old. Appendix 2.
Randomization
Pregnant women who satisfy eligibility criteria will be ran-
domized into one of two groups: 1) aerobic exercise group
(controlled by a physical therapist and a nurse, and 2)
usual prenatal control. Randomization will be performed
using a variable blocking desing with a permuted block of
maximum 8 subjects. Exercise will start only when each
block is completed; because it consists of supervised ses-
sions in groups of 3 to 5 women. Randomization will be
administrated only by the coordinator of study, who is
not involved in the intervention or in the measuring of
clinical parameters. Given the nature of the interventions,
it is not possible to blind the participating individuals.
Instead, a research assistant at each site will control all the
primary and secondary outcome assessments in order to
blind to treatment assigned. While no specific qualifica-
tions or experience are required of the research assistants,
training will be provided prior to the initiation of the trial
about protocol and measurement procedures and meth-
ods used to maintain the blind. These procedures are also
detailed in the study operations manual. Moreover, the
importance of maintaining the blinding and allocation
concealment will be reinforced by regularly scheduled
conference calls at the sites and daily meetings with the
camp investigators. Figure 2.
Procedures
Enrollment
This study will be performed in pregnant women with an
anticipated enrollment period of 12 months. Screening of
participants will consist in the evaluation of inclusion and
exclusion criteria, explanation of the study protocol, and
Study design Figure 2
Study design.Trials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
Page 5 of 10
(page number not for citation purposes)
the assessment of the willingness to participate in the
study. Eligible subjects will be scheduled to the following
visits:
- Visit A: to perform a structured validated interview
(socio-demographic data, habits, medical record) and a
detailed physical examination. Prenatal care visits will be
continued in the primary care center assigned as part of
her health insurance plan.
Baseline assessments and active follow-up
- Visit B: will include measurements of blood pressure,
anthropometric parameters, FMD, functional capacity
(VO2Max) and electrocardiogram. A fasting blood sample
will be obtained to determine glucose and insulin levels,
lipid profile, high sensitivity C - reactive protein (hs-CRP),
nitrates, nitrites, cGMP. During this visit participants will
be randomized to one of the two groups. For this purpose,
a randomization system using maximum blocks of 8 will
be used.
- Visit C: At 32 week gestation repeating measurements
described above.
-  Visit D: the following pregnancy outcomes will be
recorded post partum: pregnancy duration, blood pres-
sure evolution, characteristics of childbirth (route and
duration of childbirth, postpartum hemorrhage), new-
born outcomes (gestational age at birth, Apgar score,
weight, height, head circumference and abdominal cir-
cumference in cm). With these measures variables will be
constructed: (weight/height3), head circumference/birth
weight and weight/height indexes [30]. In addition, the
number of prenatal controls and information regarding
pregnancy complications will be registered.
Passive follow-up
All the women included in the study will undergo a pas-
sive follow-up post delivery control 30 days after delivery
(by phone).
Blood samples
In fasting conditions (at least 10 hours), blood samples
will be withdrawn from the antecubital vein, with appro-
priate conditions of asepsis and antisepsis, using 3 vacu-
tainer tubes, one dry, another with citrate, and the other
containing EDTA. After 10 minutes in vertical position, all
samples will be centrifuged at 3000 rpm during 15 min-
utes to extract the serum or plasma. Part of the samples
obtained during visits B and C will be stored in Eppendorf
vials at -70°C until the end of the study.
Physical measurements
Anthropometric will be performed in each participant at
enrollment and before delivery. Standard measurements
will be performed in duplicate by the same examiner on
each woman. All determinations will be realized in fasting
patients, wearing light clothes and without shoes, using
standardized formats and methods [31].
Weight: will be measured with the patient standing and
then registered after rounding it to the nearest 200 grams.
The weight scale will be calibrated to 0 before each meas-
urement.
Height: will be measured using a metric tape with the
patient standing against the wall in Frankfort's position,
and the value marked by a ruler placed horizontally on
the head of the patient.
Heart rate: number of beats per minute will be measured
in the radial artery.
Blood pressure: will be taken twice (with a difference of
5 minutes between the measurements) using a mercury
sphygmomanometer on the right arm, with the patient
comfortably seated, after a 5 minute rest. Systolic blood
pressure (SBP) will be determined by the first audible
sound (Korotkoff phase 1). Diastolic blood pressure
(DBP) will be registered when the sound disappears
(Korotkoff phase 5) [32]. The patient should not have
smoked 30 minutes prior to the blood pressure measure-
ment. The pneumatic arm cuff must cover 2/3 of the
upper arm's length; its inferior border must be 2-3 cm
over the antecubital space; the cuff will be slowly deflated.
The mean blood pressure (MBP), will be calculated using
the following formula [SBP+(2*DBP)]/3.
Body composition: % fat mass indirect (FM; kg), fat-free
soft tissue mass (FFT; kg), will be measured at baseline
and follow-up visits using indirect formulas [33].
Body Mass Index (BMI): This index will be estimated
using the weight in kilograms divided by the second
power of the height expressed in meters.
Physical exercise protocol (Functional Capacity)
To determine the pregnancy-specific anaerobic threshold
(AT), all women will perform an incremental exercise sub-
maxim test of the ramp type on a mechanically braked
cycloergonometer (Monarck 820K.) at a bench height to
facilitate the most effective pedalling. Participants will be
instructed to perform the test for as long as possible to
ensure a true maximal attempt. Standard ACSM test termi-
nation criteria will be monitored and followed through-
out each test. After a 3-minute warm-up at 20 W, the work
rate will increase every minute by 15 wattios (W).
Throughout the test the pedalling rate will be set up at 60
rpm. The pregnant women will be monitored by blood
pressure and heart rate, and will be required to estimateTrials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
Page 6 of 10
(page number not for citation purposes)
their level of exhaustion every minute on Borg's Ratio of
Perceived Exertion scale. The incremental workload will
be discontinued when one of the following criteria will be
met: heart rate of 160 beat per minute, or the maximum
level of exhaustion on Borg's scale; another 3-minute
workload will be realized at 10 W followed for cooling
down before completion of the exercise test.
Measurement of flow-mediated dilatation of the brachial artery
Endothelium-dependent vasodilatation will be measured
using the technique introduced by Celermajer et al. [23],
using the guidelines reported by Corretti et al. [34]. The
diameter of the brachial artery will be assessed using a
high-resolution ultrasound device (Siemens SG-60, USA),
equipped with a 7.5 MHz linear array transducer and an
integrated electrocardiography package. The ultrasound
procedures will be performed with the subject resting qui-
etly in supine position for at least 10 minutesAll measure-
ments will be taken at end-diastole triggered by
electrocardiogram. First, the diameter of the right brachial
artery will be searched in a cross-sectional view and then
scanned over a longitudinal section 5 to 10 cm proximal
to the right elbow. The diameter of the brachial artery will
be measured from the anterior to the posterior intima/
lumen interface at a fixed distance. The mean diameter
will be calculated from 4 cardiac cycles. After that, a pneu-
matic tourniquet placed around the right forearm will be
rapidly inflated to at least 50 mm Hg above the systolic
blood pressure for 5 minutesA sudden release of the cuff
will induce an increase in blood flow in the brachial artery
located proximal to the tourniquet. During reactive hyper-
emia, there will be an increase in shear stress, causing
endothelium-dependent vasodilatation, mainly due to
endothelial release of nitric oxide [35]. This secondary
dilation enhances and prolongs the reactive hyperaemic
phase. FMD of the brachial artery will be measured 45-60
s after cuff release. The change in diameter caused by the
increased flow will be calculated as the percentage change
relative to the baseline measurement (FMD%). The dila-
tor brachial artery response due to shear stress has been
shown to have a good accuracy and reproducibility
[24,36,37]. Images will be recorded on DVD player, and
the measurements will be done by two observers blinded
to the study and then both measurements will be aver-
aged.
Biochemical markers
The routine clinical test and those of the endothelial func-
tion and inflammation markers will be processed in the
Proteins, Enzymes and Biochemistry Laboratory, from the
Universidad of Valle (Cali, Colombia).
Plasma glucose levels: Glucose levels will be measured by
enzyme assay kits, using the A-15 analyser (Biosystems,
España).
Insulin: Insulin will be determined by chemiluminescent
immunometric assay (IMMULITE® Automated Analyzer,
Diagnostic Products Corporation, Los Angeles, USA).
Lipid profile: Total cholesterol, triglycerides and HDL
cholesterol (HDL-C) levels will be measured by enzyme
assay kits, using the A-15 analyser (Biosystems, Spain).
Estimates of LDL-C concentration will be calculated using
the Friedewald formula [38].
High-sensitivity C - reactive protein (CRP): the fasting
plasma CRP concentrations will be analyzed by high sen-
sitivity turbid meter technique using the use automatic
analyzer and reagents (Biosystems, Spain) [39].
Biomarkers of the endothelial function. Measurement
of the NO in serum: NO is rapidly converted to nitrate
and nitrite. The measurement of these metabolites are
used to estimate NO production The NOx (nitrate plus
nitrite), concentrations in serum will be determined using
a commercial kit (Nitrate/Nitrite Colorimetric Assay Kit,
Cayman Chemical, USA). The within-day and between-
day coefficients of variation for this assay are less than 5%
at a concentration of 50 μmol/l [40]. Subjects will receive
a standardized low-nitrate diet for 24 hours before testing
to avoid the effect of nitrates in the diet.
Measurement of the cGMP Level in Plasma: blood will
be collected in citrate anticoagulated tubes and immedi-
ately centrifuged. Plasma will be deproteinized by addi-
tion of 25 volumes of absolute ethanol and boiled before
centrifugation. After evaporation, the sample will be dis-
solved in 0.05 mol/L Na-acetate buffer, pH 6.2. cGMP will
be acetylated to be measured by radioimmunoassay after
succinylation (Kit Colorimetric Assay. Cayman Chemical,
USA) [41].
Nutrition
The pregnant women will answer three nutritional ques-
tions: 1) Did the participant eat meat the week before and
if so, how much, 2) Did the participant eat fried food the
week before and if so how often, and 3) How often did the
participant eat vegetables the previous week [42].
Statistical Analysis
There will be an exploratory analysis which will include
mean values and standard deviations of each of the varia-
bles studied to determine the balance at baseline between
the groups. Normality of distribution will be checked for
all variables using the Kolmogorov-Smirnov test.
The primary outcome will be the differences on endothe-
lium-dependent brachial artery flow-mediated dilatation
between the groups; and the secondary outcomes will be
the differences related to anthropometric, functional andTrials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
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metabolic parameters, and pregnancy outcomes. The
comparison between the groups will be made after treat-
ment using the student t test for those variables with nor-
mal distribution and the non parametric Mann-Whitney
test for those with non-normal distribution. Then, a linear
regression analysis will be performed to determine the
effect for each variable on the FMD, modeling it with
Greenland parameters to determine which variable has a
relationship with the model. Statistical analyses will be
carried out using the SPSS software (version 14.0, SPSS,
Chicago, IL). A p value < 0.05 will be considered statisti-
cally significant.
Study conduct and monitoring
The study will be conducted according to Good Clinical
Practice and standard operating procedures. It will be
monitored by the Human Rights Committee at the Uni-
versidad del Valle Coordinating Center composed of
experts in physical exercise, physicians, gynecologists,
nurses, physical therapists, physical educators, clinical
epidemiologists and bacteriologists. Interim monitoring
reports will be submitted to the experts, focusing on
patient intake, adherence to protocol, baseline compara-
bility of treatment groups, completeness of data retrieval,
and adverse events. All adverse events will also be
reported to the Universidad del Valle Ethics Committee.
To standardize study procedures, an operations manual
has been written and comprehensive training sessions will
be held prior to the initiation of the trial. In addition,
there will be weekly conference calls between the sites, the
Coordinating Center, and the research chief to review pro-
cedures and address problems. To ensure the uniformity
and quality of the interventions at each site, experts in
exercise physiology will train all the therapists prior to the
trial initiation and consult with them on an ongoing
basis. The Coordinating Center has initiated procedures to
ensure the quality and integrity of the data. These include
inspections of the data forms as they are received from
sites and periodic reviews of the computer data files to
identify out of range values and missing data forms.
Ethical aspects
The clinical trial will be conducted according to the Hel-
sinki's Declaration, the Good Clinical Practice Guidelines
and the Colombian legislation (Resolution 8430/93 of
the Ministry of Health). The patient will provide written
informed consent in a form designed for such purpose.
The information generated by the study will be confiden-
tial and strictly limited to the purposes stipulated in the
protocol. The patient may refuse to continue participating
in the study at any moment after providing consent. The
study has been approved by both Universidad del Valle
Ethics committee and that of Fundación Cardiovascular
de Colombia. All assessments will be performed by
trained staff. The blood samples will be collected in asep-
tic conditions by an expert bacteriologist. A complete
description of the design and methods of this RCT, which
was in accordance with CONSORT guidelines http://
www.consort-statement.org was recently published [43].
Study timeline
The study will last 36 months. Figure 3.
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Appendices




￿ Overview of treatment
￿ Instructions on how to keep activity diary; how to
select activities based on PER.
Session 2
￿ Watch videotape on stretching and review stretching
￿ Supervised stretching
￿ Check activity diaryTrials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
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Session 3
￿ Instruct pregnant women about ways to incorporate
activities into lifestyle
￿ Check activity diary
Session 4
￿ Watch videotape on relaxation exercises
￿ Supervised exercises
￿ Check activity diary
Session 5
￿ Instructions on maternal nutrition
￿ Check alimentation diary
Session 6
￿ Instructions on intrauterine stimulation
￿ Supervised activity
￿ Check activity diary
Study Timeline Figure 3
Study Timeline. CRF: Case report format.Trials 2009, 10:104 http://www.trialsjournal.com/content/10/1/104
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Appendix 2. Selection criteria
Inclusion Criteria:
▪ Nulliparous women who have not participated in a
structured exercise program during pregnancy.
▪ Living fetus at the routine ultrasound scan and a normal
pregnancy.
▪ Gestational age 16 to 20 weeks.
▪ Written informed consent will be obtained from each
woman prior to the inclusion in the study.
Exclusion Criteria:
▪ History of high blood pressure.
▪ Chronic medical illnesses (cancer, renal, endocrinologic,
psychiatric, neurologic, infectious and cardiovascular dis-
eases).
▪ Persistent bleeding after week 12 of gestation.
▪ Poorly controlled thyroid disease.
▪ Placenta praevia, incompetent cervix, polyhydramnios,
oligohydramnios.
▪ History of miscarriage in the last twelve months.
▪ Diseases that could interfere with participation (follow-
ing recommendations from ACSM 2000, ACOG 2002).
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